Research programme: CNS disorder therapeutics - Promentis Pharmaceuticals

Drug Profile

Research programme: CNS disorder therapeutics - Promentis Pharmaceuticals

Alternative Names: Antioxidants - Promentis Pharmaceuticals; Glutamate signalling modulators - Promentis Pharmaceuticals; SXC 2023

Latest Information Update: 29 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Marquette University; Promentis Pharmaceuticals; University of Wisconsin at Milwaukee
  • Developer Promentis Pharmaceuticals
  • Class Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Antioxidants; Glutamate receptor modulators; SLC7A11 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Psychiatric disorders
  • Research Pervasive child development disorders
  • No development reported Parkinson's disease; Schizophrenia

Most Recent Events

  • 30 Mar 2017 Preclinical trials in Psychiatric disorders in USA (unspecified route)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinson's-disease in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Schizophrenia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top